

# Chronic Kidney Disease: Detection and Evaluation

DAVID Y. GAITONDE, MD; DAVID L. COOK, MD; and IAN M. RIVERA, MD

*Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia*

Chronic kidney disease affects 47 million people in the United States and is associated with significant health care costs, morbidity, and mortality. Because this disease can silently progress to advanced stages, early detection is critical for initiating timely interventions. Multiple guidelines recommend at least annual screening with serum creatinine, urine albumin/creatinine ratio, and urinalysis for patients with risk factors, particularly diabetes mellitus, hypertension, and a history of cardiovascular disease. The U.S. Preventive Services Task Force found insufficient evidence to assess the balance of benefits and harms of screening for chronic kidney disease in the general population, and the American College of Physicians recommends against screening asymptomatic adults without risk factors. Persistently elevated serum creatinine and albuminuria are diagnostic and prognostic hallmarks of chronic kidney disease. Lower levels of albuminuria are associated with adverse renal and cardiovascular outcomes. Serum cystatin C is a novel biomarker that is most useful when a false-positive decreased estimated glomerular filtration rate calculated from serum creatinine is suspected. New guidelines incorporate albuminuria into the classification framework for chronic kidney disease and elaborate on identification of the disease, the frequency of follow-up, and recommendations for nephrology referral. Nephrology consultation is indicated for patients with an estimated glomerular filtration rate less than 30 mL per minute per 1.73 m<sup>2</sup>, persistent urine albumin/creatinine ratio greater than 300 mg per g or urine protein/creatinine ratio greater than 500 mg per g, or if there is evidence of a rapid loss of kidney function. A multidisciplinary approach between primary care physicians, nephrologists, and other subspecialists for implementing early interventions, providing education, and planning for advanced renal disease is key for effective management. (*Am Fam Physician*. 2017;96(12):776-783. Copyright © 2017 American Academy of Family Physicians.)

 More online at <http://www.aafp.org/afp>.

**CME** This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz on page 772. Author disclosure: No relevant financial affiliations.

**► Patient information:** A handout on this topic, written by the authors of this article, is available at <http://www.aafp.org/afp/2017/1215/p776-s1.html>.

**C**hronic kidney disease (CKD) is a major public health concern that affects approximately 47 million persons in the United States, or 14.8% of the U.S. adult population.<sup>1</sup> It is associated with significant health care costs, morbidity, and mortality.<sup>1,2</sup> The presence of CKD increases the risk of hospitalization, cardiovascular events, and death.<sup>3,4</sup> Recent data show that the prevalence of CKD has largely stabilized since 2004, possibly because of better awareness and treatment of obesity, hypertension, and diabetes mellitus.<sup>5</sup> A 2014 report showed that Medicare spending for patients with CKD was more than \$52 billion, which represents 20% of all Medicare costs.<sup>6</sup> The per-person per-year Medicare expense for CKD rises with increasing disease severity, ranging from \$1,700 for stage 2 to \$12,700 for stage 4, with costs rising exponentially in end-stage renal disease.<sup>2,6</sup> Thus, early detection of CKD is

critical to slow disease progression, prevent long-term morbidity and mortality, and decrease health care spending. The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Work Group published updated guidelines on the detection, evaluation, classification, and management of CKD.<sup>7</sup> This article reviews current recommendations for the primary care physician.

## Detection of CKD

CKD is defined as abnormal kidney structure or function lasting more than three months with associated health implications.<sup>7</sup> Indicators include albuminuria, urine sediment abnormalities, abnormal renal imaging findings, serum electrolyte or acid-base derangements, and glomerular filtration rate (GFR) less than 60 mL per minute per 1.73 m<sup>2</sup>.

Because CKD can progress to advanced renal failure, end-stage renal disease, and

**Table 1. Stages of Chronic Kidney Disease and Recommended Action Plan**

Stage	Description	Estimated GFR (mL per minute per 1.73 m <sup>2</sup> )	Action plan
1	Kidney damage* with normal or increased GFR	≥ 90	Diagnose and treat chronic kidney disease and comorbid conditions, slow progression, reduce cardiovascular risk
2	Kidney damage* with mildly decreased GFR	60 to 89	Estimate progression
3a	Mildly to moderately decreased GFR	45 to 59	Evaluate and treat complications
3b	Moderately to severely decreased GFR	30 to 44	Evaluate and treat complications
4	Severely decreased GFR	15 to 29	Prepare for renal replacement therapy
5	Kidney failure	< 15 (or dialysis)	Renal replacement therapy if uremia present

GFR = glomerular filtration rate.

\*—Markers of kidney damage are required for diagnosis of stage 1 or 2 chronic kidney disease.

Adapted with permission from National Kidney Foundation. *K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification*. Am J Kidney Dis. 2002;39(2 suppl 1):S216, with additional information from references 21 and 23.

even death, early detection is critical for initiating timely therapeutic interventions, limiting nephrotoxin exposure, preventing further reduction in GFR, and preparing for renal replacement therapy.<sup>8,9</sup>

#### SCREENING INDICATIONS

Multiple guidelines recommend that patients with diabetes or hypertension be screened annually for CKD. Furthermore, patients with other risk factors, including cardiovascular disease, older age, history of low birth weight, obesity, and a family history of CKD, warrant consideration for screening.<sup>7,10,11</sup> The U.S. Preventive Services Task Force concluded that the evidence is insufficient to assess the balance of benefits and harms of routine screening for CKD in asymptomatic adults.<sup>12</sup> The American College of Physicians and the American Academy of Family Physicians recommend against screening for CKD in asymptomatic adults without risk factors.<sup>13,14</sup>

#### SCREENING TESTS

Screening for CKD includes measurement of serum creatinine, estimation of GFR using a serum creatinine-based equation, measurement of the urine albumin/creatinine ratio, and urinalysis.<sup>7</sup> Urinalysis has a high sensitivity for heavy proteinuria (greater than 300 mg per 24 hours, as estimated from the spot urine protein/creatinine ratio) but may not detect clinically significant lower levels (30 to 300 mg).<sup>15</sup> Because albumin is the predominantly filtered glomerular protein, initial proteinuria evaluation using the spot urine albumin/creatinine ratio obtained from an early morning sample is recommended.<sup>7,16,17</sup> Timed 24-hour urine collections are no longer recommended as an initial diagnostic tool because of the potential for inadequate collection, inconvenience to patients, and the lack of diagnostic advantage over the urine albumin/creatinine ratio.

#### GFR ESTIMATION

Steady state renal function is best determined by estimation of GFR, which is derived from measurement of serum creatinine. The Cockcroft-Gault equation to estimate GFR is now used only to determine dosing adjustments for medications.<sup>18,19</sup> For all other purposes, the Chronic Kidney Disease Epidemiology Collaboration equation ([http://www.kidney.org/professionals/kdoqi/gfr\\_calculator.cfm](http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm)) is the established method of estimating GFR in routine clinical practice because of improved accuracy in persons with near-normal estimated GFR<sup>20</sup> (eTable A). Updated GFR categories and terminology are provided in Table 1.<sup>21-23</sup>

Serum cystatin C is a filtration marker that has emerged as an alternative to serum creatinine to more accurately estimate GFR and classify CKD. Obtaining the serum cystatin C–based estimated GFR is most beneficial when a false-positive decreased estimated GFR is suspected, such as in a patient without known structural kidney disease, risk factors for CKD, or albuminuria who has a creatinine clearance–calculated estimated GFR of 45 to 59 mL per minute per 1.73 m<sup>2</sup>.<sup>24</sup> In such cases, the serum cystatin C and serum creatinine levels can be obtained concurrently for recalculation of the estimated GFR using the appropriate calculator<sup>7,24,25</sup> (eTable A). If the estimated GFR calculated using both serum creatinine and serum cystatin C is greater than 60 mL per minute per 1.73 m<sup>2</sup>, a diagnosis of CKD is not warranted. A recent community-based longitudinal observational study demonstrated that a reduced serum cystatin C–based estimated GFR was associated with all-cause and cardiovascular disease mortality.<sup>26</sup> It should be noted that serum cystatin C is not reliable in patients with acute kidney injury, inflammatory states, or thyroid dysfunction.<sup>7,16,25,27</sup> Furthermore, it is not yet universally available and may add significant cost to the evaluation.

## Markers of Kidney Damage

### PROTEINURIA

Persistent proteinuria is a defining marker of renal injury regardless of estimated GFR, and it identifies increased cardiovascular disease and mortality risks.<sup>17,28</sup> Measurement of proteinuria with the total protein/creatinine ratio is a less sensitive method than the spot albumin/creatinine ratio, and includes filtered albumin, tubular-secreted proteins (Tamm-Horsfall protein), and plasma proteins from other disease processes, such as multiple myeloma and infection. Because the protein/creatinine ratio is less sensitive for low-level proteinuria (less than 150 mg per 24 hours as estimated from the spot urine protein/creatinine ratio), it should not be routinely used for initial screening.

### ALBUMINURIA

The spot urine albumin/creatinine ratio is preferred over the protein/creatinine ratio because it detects lower levels of proteinuria. Small amounts of albumin in the urine—between 30 and 300 mg per day—were previously thought to be clinically insignificant. However, modest albuminuria is now recognized to have prognostic significance, and the albumin/creatinine ratio is recommended by current clinical practice guidelines that emphasize albuminuria.<sup>7</sup> Menstrual bleeding, urinary tract infection, exercise, and other factors may affect the urinary albumin/creatinine ratio.<sup>7</sup>

To further risk stratify and optimize early detection of albuminuria in at-risk persons, the terms microalbuminuria and macroalbuminuria have been replaced with normal to mildly increased (albumin/creatinine ratio less than 30 mg per g), moderately increased (30 to 300 mg per g), and severely increased (greater than 300 mg per g).<sup>7</sup> Severe albuminuria independently predicts mortality and end-stage renal disease.<sup>29</sup> Dipstick urinalysis is not sensitive for detection of small amounts of albumin and is no longer recommended for routine screening or definitive diagnosis.<sup>7</sup> Updated proteinuria categories and terminology are provided in the KDIGO 2012 guideline (see Table 7, “Relationship Among Categories for Albuminuria and Proteinuria” at [http://www.kdigo.org/clinical\\_practice\\_guidelines/pdf/CKD/KDIGO\\_2012\\_CKD\\_GL.pdf](http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf)).<sup>7</sup>

### OTHER INDICATORS

Urinalysis and urine microscopy still play significant roles in the detection of CKD. Presence of hematuria, cellular casts, chronic pyuria, tubular concentrating defects, and insufficient renal acidification all suggest renal impairment in the correct clinical context. Patients

with diabetes and albuminuria have a high risk of progressing to end-stage renal disease as proteinuria worsens.<sup>17</sup> Individuals with CKD and diabetes should have a comprehensive evaluation that addresses hypertension and cardiovascular risk to guide future therapeutic interventions.<sup>23</sup> Moderate to advanced diabetic kidney disease can potentially be diagnosed without renal biopsy and is based on clinical and laboratory evaluation (*eTable B*). However, mild diabetic kidney disease may present more subtly.

## CKD Staging

Prognosis, evaluation, and management of CKD are dependent on staging. The 2012 KDIGO guidelines provide an enhanced classification framework for CKD and albuminuria.<sup>7</sup> They also elaborate on the identification and prognosis of CKD, frequency of follow-up, and recommendations for nephrology referral. Primary care physicians should classify CKD based on the estimated GFR and degree of albuminuria (see Figure 17, Guide to Frequency of Monitoring [number of times per year] by GFR and Albuminuria Category, at [http://www.kdigo.org/clinical\\_practice\\_guidelines/pdf/CKD/KDIGO\\_2012\\_CKD\\_GL.pdf](http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf)).<sup>7</sup> Renal transplant recipients are considered to have CKD regardless of GFR or absence of albuminuria.

## Evaluation of CKD

Once reduced GFR and/or presence of proteinuria are determined to be chronic and stable (unchanged for more than three months), a comprehensive initial workup is necessary to determine the etiology of CKD. Etiologies include hypertensive kidney disease, diabetic nephropathy, or primary or secondary glomerulonephritis.<sup>7</sup> A full medical history, including exposure to potential nephrotoxins; physical examination; and review of historical and current blood pressure, dietary history, and weight measurements are essential for CKD evaluation<sup>7</sup> (*Table 2*<sup>7,21</sup>). Laboratory assessment should include measurement of serum electrolytes, fasting lipids, A1C, and urine albumin/creatinine ratio.<sup>7</sup> Urinalysis with microscopic urine sediment is helpful if intrinsic renal disease is suspected.<sup>21</sup> Renal ultrasonography is recommended to evaluate for structural abnormalities.<sup>30</sup> *Figure 1* outlines a proposed approach to the evaluation of CKD.<sup>7</sup>

## CARDIOVASCULAR DISEASE

Because the presence of albuminuria or a GFR less than 60 mL per minute per 1.73 m<sup>2</sup> increases the risk of cardiovascular and all-cause mortality, cardiovascular risk stratification is recommended for all persons with

**Table 2. Initial Diagnostic Evaluation in Patients with Suspected CKD**

<i>Examination component</i>	<i>Clinical and diagnostic clues</i>	<i>Findings suggestive of CKD risks and etiology</i>
Review of systems	Recent infections	Poststreptococcal glomerulonephritis
	Risk factors for sexually transmitted infection or injection drug use	Hepatitis B or C, HIV infection
	Skin rash or arthritis	Autoimmune disease (e.g., cryoglobulinemia, systemic lupus erythematosus)
	Symptoms during urination	Urinary tract infection, obstruction, or stone
Medical history	Diabetes mellitus	Moderately increased albuminuria with or without retinopathy and elevated blood pressure
	Hypertension	Severely elevated blood pressure, often with target organ damage
Family history of kidney disease	Men and women are affected equally in every generation	Autosomal dominant polycystic kidney disease
	Men in every generation are affected	Sex-linked recessive disease (e.g., Alport syndrome)
	Less frequent than every generation	Autosomal recessive polycystic kidney disease
Physical examination	Abdominal findings	Bruit (atherosclerotic renal artery stenosis, fibromuscular dysplasia), distended bladder, flank pain
	Cardiovascular findings	Heart failure, ventricular hypertrophy
	Carotid bruit	Carotid artery disease
	Decreased peripheral pulses	Peripheral vascular disease
	General findings	Cushingoid appearance, edema
	Increased blood pressure and weight	Hypertension, obesity
	Musculoskeletal findings	Arthritis, synovitis
	Ophthalmoscopic findings	Hypertensive or diabetic retinal disease
	Skin changes	Rash and skin changes in autoimmune disease or neurofibromatosis
Laboratory tests	Abnormal serum and urine protein electrophoresis	Amyloidosis, light chain deposition disease, multiple myeloma
	Decreased serum complement levels C3 and C4	Cryoglobulinemia, lupus nephritis, membranoproliferative glomerulonephritis, poststreptococcal glomerulonephritis
	Dysmorphic urinary red blood cells or red blood cell casts	Immunoglobulin A nephropathy, rapidly progressive glomerulonephritis
	Eosinophilia	Atheroembolic disease, tubulointerstitial disease
	Positive antiglomerular basement membrane antibody test	Antiglomerular basement membrane-associated rapidly progressive glomerulonephritis, Goodpasture syndrome
	Positive antineutrophil cytoplasmic antibody test	Granulomatosis with polyangiitis, microscopic polyangiitis, pauci-immune rapidly progressive glomerulonephritis
	Positive antinuclear antibody test	Lupus nephritis
	Positive cryoglobulin test	Cryoglobulinemia
	Positive hepatitis B serology*	Membranoproliferative nephritis, membranous nephropathy
	Positive hepatitis C serology*	Mixed cryoglobulinemia, membranoproliferative glomerulonephritis, membranous nephropathy
Positive HIV serology*	Focal and segmental glomerulosclerosis	
Ultrasonography	Doppler ultrasonography	May be useful in investigation of venous thrombosis, less so in arterial stenosis
	General findings	May show nephrocalcinosis, discrete stones, hydronephrosis, cysts,† or masses
	Increased echogenicity	May indicate cystic disease or medical renal disease
	Large kidneys	Generally indicate tumors, infiltrating diseases, or diseases causing nephrotic syndrome, including diabetic nephropathy
	Size disparities and scarring	Suggest vascular, urologic, or tubulointerstitial diseases due to stones or infection
	Small hyperechoic kidneys	Generally indicate long-standing CKD


CKD = chronic kidney disease; HIV = human immunodeficiency virus.

\*—Routine laboratory tests; other laboratory tests ordered for targeted evaluation.

†—Simple cysts and duplicated collection systems are considered normal variants and are not indicative of kidney damage. Complex cysts or masses require urologic evaluation to rule out malignancy.

Information from references 7 and 21.

# Assessment of Patients at Risk of CKD



\*—Monitoring guidelines are available in the 2012 Kidney Disease: Improving Global Outcomes recommendations (see Guide to Frequency of Monitoring [number of times per year] by GFR and Albuminuria Category in chapter 2.1.4 at [http://www.kdigo.org/clinical\\_practice\\_guidelines/pdf/CKD/KDIGO\\_2012\\_CKD\\_GL.pdf](http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf)).

†—Markers of kidney damage include, but are not limited to: structural renal disease (i.e., atrophic kidneys, thin [ $< 1$  cm] renal cortices, hyperechoic kidneys on ultrasonography), hematuria (microscopic or otherwise), presence of cellular casts, chronic pyuria, tubular concentrating defects, and insufficient renal acidification.

**Figure 1.** Assessment algorithm for patients at risk of CKD. (CKD = chronic kidney disease; GFR = glomerular filtration rate.)

Information from reference 7.

**Table 3. Clinical Interventions for Adults with Chronic Kidney Disease**

<i>Clinical finding</i>	<i>Stage</i>	<i>Parameters to assess</i>	<i>Frequency of evaluation</i>
Anemia	All	Complete blood count with differential; reticulocyte count; iron, ferritin, and transferrin levels	Once per year (more frequently if abnormal)
Malnutrition	3a to 5	Weight, serum albumin level, dietary history	Every six to 12 months in stages 3a/b; every one to three months in stages 4 and 5. Consider nutrition referral starting at stage 4
Mineral and bone disorder	3a to 5	Alkaline phosphatase level	Once in stage 3a/b; every 12 months in stages 4 and 5
		Calcium and phosphorus levels	Every three to six months in stages 3a/b and 4; every one to three months in stage 5
		Consider dual energy x-ray absorptiometry	No routine testing in stages 3a to 5; routine testing is permissible in stages 1 and 2
		25-hydroxyvitamin D level	Once, then as indicated in stage 3a/b; every three to six months in stage 4; every one to three months in stage 5
		Parathyroid hormone level	Once, then as indicated in stage 3a/b; every three to six months in stage 4; every one to three months in stage 5
Neuropathy	3a to 5	Paresthesia, mental status, sleep disturbances (e.g., restless legs syndrome); consider sleep study and nerve conduction study	As indicated
Reduced level of functioning and well-being	3a to 5	Health literacy assessment, social support, standardized self-administered instruments (e.g., Dartmouth-Northern New England Primary Care Cooperative Information Project charts, Duke Health Profile, 36-item Medical Outcomes Study [SF-36], Kidney Disease Quality of Life Instrument)	Once, then as indicated

*Adapted with permission from Baumgarten M, Gehr T. Chronic kidney disease: detection and evaluation. Am Fam Physician. 2011;84(10):1146.*

CKD.<sup>7,31</sup> Furthermore, the presence of CKD should not preclude antiplatelet agents or therapies for heart failure if indicated.<sup>7</sup> GFR and serum electrolyte levels should be monitored as pharmacotherapy for the management of heart failure is escalated, because these parameters may change significantly. Electrocardiography and echocardiography may be useful in identifying end-organ damage from long-standing, poorly controlled hypertension as a potential clue to the etiology of CKD.

#### **ANEMIA**

Patients with CKD are at increased risk of anemia and mineral and bone disorders. Hemoglobin should be measured at least annually in patients with stage 3 CKD, and more frequently as renal function declines.<sup>7,32</sup> A complete blood count, absolute reticulocyte count, ferritin level, transferrin saturation, and vitamin B<sub>12</sub> and folate levels should be obtained in patients with anemia.<sup>32</sup> There is no role for measurement of serum erythropoietin level in the primary care setting.

#### **MINERAL AND BONE DISORDERS**

Patients with stage 1 to 3a CKD can be screened for osteoporosis using the same strategy as the general population.

For those with more advanced CKD, densitometry is not recommended because fracture risk prediction is less accurate.<sup>7,33</sup> Additionally, certain subsets of metabolic bone disease (e.g., adynamic bone disease) are not detected by densitometry.<sup>7,33</sup> Bone biopsy is the diagnostic procedure of choice to evaluate for possible adynamic bone disease in patients with advanced CKD. Patients with stage 3a to 5 CKD should have serum calcium, phosphorus, 25-hydroxyvitamin D, parathyroid hormone, and alkaline phosphatase levels checked regularly; abnormal levels may indicate the presence of renal mineral and bone disorders.<sup>7,33</sup> Consultation with a nephrologist and/or endocrinologist is recommended for patients with advanced kidney disease in whom renal mineral and bone disorder is suspected. Details of these and other interventions for patients with CKD are outlined in *Table 3*.<sup>21</sup>

#### **Indications for Nephrology Referral**

Nephrology consultation is indicated when the estimated GFR is less than 30 mL per minute per 1.73 m<sup>2</sup>, or earlier if necessary (*Table 4*).<sup>7,34</sup> For patients with progressive CKD, referral to a nephrologist for renal replacement therapy is essential when the risk of renal failure within one year is 10% to 20%. Validated risk calculators for

## SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	References
The initial evaluation of GFR should include measurement of serum creatinine and estimation of the GFR using a creatinine-based equation.	C	7
An early morning spot urine albumin/creatinine ratio is the preferred initial test to measure proteinuria in patients undergoing CKD evaluation.	C	7, 16, 17
Serum cystatin C should be measured to determine whether decreased GFR represents a false positive in patients who have elevated serum creatinine levels, but no known CKD, no risk factors for CKD, and no albuminuria.	C	24
CKD should be classified using the estimated GFR and the degree of albuminuria.	C	7
Patients with CKD should have serum hemoglobin measured at least annually, and more often depending on the severity of CKD.	C	7, 32
Routine evaluation of bone density should not be performed in patients with an estimated GFR < 45 mL per minute per 1.73 m <sup>2</sup> because results may be inaccurate.	C	7, 33
The evaluation of patients with stage 3a to 5 CKD (estimated GFR < 45 mL per minute per 1.73 m <sup>2</sup> ) should include measurement of serum calcium, phosphorus, parathyroid hormone, alkaline phosphatase, and 25-hydroxyvitamin D levels.	C	7, 33

CKD = chronic kidney disease; GFR = glomerular filtration rate.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort>.

### Table 4. Indications for Considering Nephrology Referral for Patients with CKD

#### Diagnosis of CKD cause

- Acute kidney injury (unresponsive to initial management)\*
- Anemia of CKD
- Family history of kidney disease
- Presence of red blood cell casts in the urine
- Progression of CKD†

#### Management of CKD complications

- Anemia of chronic kidney disease when hemoglobin < 10 g per dL (100 g per L)
- CKD and refractory hypertension
- Mineral and bone disorder of CKD
- Persistent abnormalities in serum potassium
- Persistent elevated albuminuria (albumin/creatinine ratio > 300 mg per g [ $> 30$  mg per mmol]) or refractory proteinuria (urinary protein/creatinine ratio > 500 to 1,000 mg per g [ $> 50$  to 100 mg per mmol])
- Recurrent nephrolithiasis or concern for nephrocalcinosis

#### Preparation for renal replacement therapy

- GFR < 30 mL per minute per 1.73 m<sup>2</sup> (KDIGO GFR categories G4 and G5)

CKD = chronic kidney disease; GFR = glomerular filtration rate; KDIGO = Kidney Disease: Improving Global Outcomes.

\*—Acute kidney injury is defined by the KDIGO guidelines as an increase in serum creatinine  $\geq 0.3$  mg per dL ( $\geq 27$   $\mu$ mol per L) within 48 hours; or an increase in serum creatinine to  $\geq 1.5$  times baseline, which is known or presumed to have occurred within the prior seven days; or urine volume < 0.5 mL per kg per hour for six hours.

†—A definitive drop in estimated GFR is manifested as a reduction in GFR category (KDIGO G1 to G5) associated with a 25% or more decline in estimated GFR from baseline. Rapid progression is a sustained decline in estimated GFR of more than 5 mL per minute per 1.73 m<sup>2</sup> per year.

Information from references 7 and 34.

progression to end-stage renal disease are available at <http://kidneyfailurerisk.com/>.<sup>27</sup> A multidisciplinary approach between primary care physicians and nephrologists for implementing early interventions, providing education, and planning for advanced renal disease is key for effective management of CKD.

This article updates previous articles on this topic by Baumgarten and Gehr,<sup>21</sup> and by Snyder and Pendergraph.<sup>35</sup>

**Data sources:** We searched the websites of the National Kidney Foundation, Kidney Disease: Improving Global Outcomes, Centers for Disease Control and Prevention, American Diabetes Association, American Medical Association, United States Renal Data System, PubMed, U.S. Preventive Services Task Force, UpToDate, and the World Health Organization. The following search terms were entered: Medicare, chronic kidney disease, dialysis, proteinuria, albuminuria, diabetic kidney disease, hypertension, renal ultrasound, urinalysis, anemia, lipid, cardiovascular disease, mortality, bone densitometry, and bone and mineral disease. Search dates: October 15, 2016, through November 20, 2017.

The views expressed in this article are those of the authors and do not necessarily reflect the official policy of the Department of Defense, Department of Army, U.S. Army Medical Department, or the U.S. government.

### The Authors

DAVID Y. GAITONDE, MD, is chief of endocrinology services and core clinical faculty at Dwight D. Eisenhower Army Medical Center, Fort Gordon, Ga.

DAVID L. COOK, MD, is a third-year internal medicine resident at Dwight D. Eisenhower Army Medical Center.

IAN M. RIVERA, MD, is chief of nephrology services and core clinical faculty at Dwight D. Eisenhower Army Medical Center.

Address correspondence to David Y. Gaitonde, MD, Dwight D. Eisenhower Army Medical Center, 300 E. Hospital Rd., Ft. Gordon, GA 30905 (e-mail: david.gaitonde@us.army.mil). Reprints are not available from the authors.

## REFERENCES

- United States Renal Data System. 2016 Annual data report, chapter 1: CKD in the general population. [https://www.usrds.org/2016/view/v1\\_01.aspx](https://www.usrds.org/2016/view/v1_01.aspx). Accessed January 20, 2017.
- Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of CKD in the Medicare population. *J Am Soc Nephrol*. 2013; 24(9):1478-1483.
- Townsend RR. Stroke in chronic kidney disease: prevention and management. *Clin J Am Soc Nephrol*. 2008;3(suppl 1):S11-S16.
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published correction appears in *N Engl J Med*. 2008;18(4):4]. *N Engl J Med*. 2004;351(13):1296-1305.
- Murphy D, McCulloch CE, Lin F, et al.; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Trends in prevalence of chronic kidney disease in the United States. *Ann Intern Med*. 2016;165(7):473-481.
- United States Renal Data System. 2016 Annual Data Report. Vol 1, Ch 6: Medicare expenditures for persons with CKD. [https://www.usrds.org/2016/view/v1\\_06.aspx](https://www.usrds.org/2016/view/v1_06.aspx). Accessed January 21, 2017.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013;3(1):1-150.
- Giatras I, Lau J, Levey AS; Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. *Ann Intern Med*. 1997; 127(5):337-345.
- Pereira BJ. Optimization of pre-ESRD care: the key to improved dialysis outcomes. *Kidney Int*. 2000;57(1):351-365.
- Centers for Disease Control and Prevention. Chronic kidney disease (CKD) surveillance system. <https://nccd.cdc.gov/CKD/data.aspx>. Accessed January 20, 2017.
- American Diabetes Association. 3. Comprehensive medical evaluation and assessment of comorbidities [published correction appears in *Diabetes Care*. 2017;40(7):985]. *Diabetes Care*. 2017;40(suppl 1):S25-S32.
- Moyer VA; U.S. Preventive Services Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2012;157(8):567-570.
- Qaseem A, Hopkins RH Jr, Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2013;159(12):835-847.
- American Academy of Family Physicians. Clinical practice guideline: chronic kidney disease. <http://www.aafp.org/patient-care/clinical-recommendations/all/chronic-kidney-disease.html>. Accessed October 26, 2017.
- Chau K, Hutton H, Levin A. Laboratory assessment of kidney disease: glomerular filtration rate, urinalysis, and proteinuria. In: Skorecki K, et al., eds. *Brenner & Rector's The Kidney*. 10th ed. Philadelphia, Pa.: Elsevier; 2016:780-803.
- Fan L, Inker LA, Rossert J, et al. Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. *Nephrol Dial Transplant*. 2014;29(6):1195-1203.
- Ninomiya T, Perkovic V, de Galan BE, et al.; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *J Am Soc Nephrol*. 2009; 20(8):1813-1821.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16(1):31-41.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Ann Intern Med*. 1999;130(6):461-470.
- Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate [published correction appears in *Ann Intern Med*. 2011;155(6):408]. *Ann Intern Med*. 2009;150(9):604-612.
- Baumgarten M, Gehr T. Chronic kidney disease: detection and evaluation. *Am Fam Physician*. 2011;84(10):1138-1148.
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39(2 suppl 1):S1-S266.
- National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update [published correction appears in *Am J Kidney Dis*. 2013;61(6):1049]. *Am J Kidney Dis*. 2012;60(5):850-886.
- Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. *Am J Kidney Dis*. 2008;51(3):395-406.
- Inker LA, Schmid CH, Tighiouart H, et al.; CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C [published corrections appear in *N Engl J Med*. 2012;367(7):681, and *N Engl J Med*. 2012;367(21):2060]. *N Engl J Med*. 2012;367(1):20-29.
- Barr EL, Reutens A, Magliano DJ, et al. Cystatin C estimated glomerular filtration rate and all-cause and cardiovascular disease mortality risk in the general population: AusDiab study. *Nephrology (Carlton)*. 2017; 22(3):243-250.
- Tangri N, Grams ME, Levey AS, et al.; CKD Prognosis Consortium. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis [published correction appears in *JAMA*. 2016;315(8):822]. *JAMA*. 2016;315(2):164-174.
- Hillege HL, Fidler V, Diercks GF, et al.; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation*. 2002;106(14):1777-1782.
- Astor BC, Matsushita K, Gansevoort RT, et al.; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney Int*. 2011;79(12):1331-1340.
- Moghaziz S, Jones E, Schroeppel J, et al. Correlation of renal histopathology with sonographic findings. *Kidney Int*. 2005;67(4):1515-1520.
- Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. *Kidney Int Suppl*. 2013;3(3):259-305.
- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney Int Suppl*. 2012;2(4):279-335.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). *Kidney Int Suppl*. 2017;7(1):1-59.
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl*. 2012;2(1):1-138.
- Snyder S, Pendergraph B. Detection and evaluation of chronic kidney disease. *Am Fam Physician*. 2005;72(9):1723-1732.